27 results
8-K
EX-99.1
IVVD
Invivyd Inc
10 Nov 22
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
4:13pm
is attributable to wind-down of adintrevimab clinical trials and manufacturing, partially offset by contract manufacturing expenses related
8-K
EX-99.1
IVVD
Invivyd Inc
11 May 23
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
4:08pm
costs due to wind-down of adintrevimab clinical trials.
Selling, General & Administrative (SG&A) Expenses: SG&A expenses were $11.0 million
8-K
EX-99.1
IVVD
Invivyd Inc
9 Nov 23
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
4:10pm
trial costs in 2022 due to ongoing adintrevimab clinical trials, with no comparable costs during the same period in 2023 due to the wind-down
8-K
EX-99.1
IVVD
Invivyd Inc
28 Mar 24
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
7:05am
to ongoing adintrevimab clinical trials, with no comparable costs during the same period in 2023 due to the wind-down of adintrevimab clinical trials
DRS
EX-3.1
IVVD
Invivyd Inc
21 May 21
Draft registration statement
12:00am
shall be null and void ab initio, and of no force or effect:
3.3.1 liquidate, dissolve or wind-up the business and affairs of the Corporation, effect
S-1
EX-3.1
4lycvaf4
16 Jul 21
IPO registration
4:56pm
DRS/A
EX-10.7
ax25 ot6dzswgmiymv0
13 Jul 21
Draft registration statement (amended)
12:00am
S-1
EX-10.7
x21g9kh
16 Jul 21
IPO registration
4:56pm
8-K
EX-99.1
dmyuqo0weuts3
9 Feb 24
Index to Consolidated Financial Statements
4:01pm
10-K
svt6ua8f8
31 Mar 22
Annual report
8:18am
10-Q
pdxyyp
20 Sep 21
Quarterly report
4:17pm